"If you can't prioritise, rationalise and simplify, then the low-hanging fruit is probably all you're going to get to...the only way to understand your way [to the difficult things] is by removing as much noise from the system as possible."
Jonny Finlay is the CEO and founder of LockBody Therapeutics, a Centessa company, where he and his team are developing a new kind of antibody to fight cancer.
Jonny talked to us about his career, the principle of radical simplicity and the relative advantages of big Pharma and startup Biotech.
Enjoy!
